The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes
Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The opti...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/7/1643 |
| _version_ | 1797440213590474752 |
|---|---|
| author | Elisa Meldolesi Giuditta Chiloiro Roberta Giannini Roberta Menghi Roberto Persiani Barbara Corvari Claudio Coco Stefania Manfrida Carlo Ratto Viola De Luca Luigi Sofo Sara Reina Antonio Crucitti Valeria Masiello Nicola Dinapoli Vincenzo Valentini Maria Antonietta Gambacorta |
| author_facet | Elisa Meldolesi Giuditta Chiloiro Roberta Giannini Roberta Menghi Roberto Persiani Barbara Corvari Claudio Coco Stefania Manfrida Carlo Ratto Viola De Luca Luigi Sofo Sara Reina Antonio Crucitti Valeria Masiello Nicola Dinapoli Vincenzo Valentini Maria Antonietta Gambacorta |
| author_sort | Elisa Meldolesi |
| collection | DOAJ |
| description | Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a <i>p</i> < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival rate. These results, if validated by future prospective studies, can bring a valid alternative to the surgery dissection without the important side effects and permanent disabilities observed during the years. |
| first_indexed | 2024-03-09T12:04:56Z |
| format | Article |
| id | doaj.art-9f772cf0a3a541bf8242e53eaaa1f55d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:04:56Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9f772cf0a3a541bf8242e53eaaa1f55d2023-11-30T22:59:59ZengMDPI AGCancers2072-66942022-03-01147164310.3390/cancers14071643The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph NodesElisa Meldolesi0Giuditta Chiloiro1Roberta Giannini2Roberta Menghi3Roberto Persiani4Barbara Corvari5Claudio Coco6Stefania Manfrida7Carlo Ratto8Viola De Luca9Luigi Sofo10Sara Reina11Antonio Crucitti12Valeria Masiello13Nicola Dinapoli14Vincenzo Valentini15Maria Antonietta Gambacorta16Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDigestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyDepartment of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, ItalyAims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a <i>p</i> < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival rate. These results, if validated by future prospective studies, can bring a valid alternative to the surgery dissection without the important side effects and permanent disabilities observed during the years.https://www.mdpi.com/2072-6694/14/7/1643locally advanced rectal cancerlateral pelvic positive nodesradiotherapysimultaneous integrated boostchemoradiotherapy |
| spellingShingle | Elisa Meldolesi Giuditta Chiloiro Roberta Giannini Roberta Menghi Roberto Persiani Barbara Corvari Claudio Coco Stefania Manfrida Carlo Ratto Viola De Luca Luigi Sofo Sara Reina Antonio Crucitti Valeria Masiello Nicola Dinapoli Vincenzo Valentini Maria Antonietta Gambacorta The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes Cancers locally advanced rectal cancer lateral pelvic positive nodes radiotherapy simultaneous integrated boost chemoradiotherapy |
| title | The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes |
| title_full | The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes |
| title_fullStr | The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes |
| title_full_unstemmed | The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes |
| title_short | The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes |
| title_sort | role of simultaneous integrated boost in locally advanced rectal cancer patients with positive lateral pelvic lymph nodes |
| topic | locally advanced rectal cancer lateral pelvic positive nodes radiotherapy simultaneous integrated boost chemoradiotherapy |
| url | https://www.mdpi.com/2072-6694/14/7/1643 |
| work_keys_str_mv | AT elisameldolesi theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT giudittachiloiro theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertagiannini theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertamenghi theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertopersiani theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT barbaracorvari theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT claudiococo theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT stefaniamanfrida theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT carloratto theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT violadeluca theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT luigisofo theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT sarareina theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT antoniocrucitti theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT valeriamasiello theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT nicoladinapoli theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT vincenzovalentini theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT mariaantoniettagambacorta theroleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT elisameldolesi roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT giudittachiloiro roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertagiannini roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertamenghi roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT robertopersiani roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT barbaracorvari roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT claudiococo roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT stefaniamanfrida roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT carloratto roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT violadeluca roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT luigisofo roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT sarareina roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT antoniocrucitti roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT valeriamasiello roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT nicoladinapoli roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT vincenzovalentini roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes AT mariaantoniettagambacorta roleofsimultaneousintegratedboostinlocallyadvancedrectalcancerpatientswithpositivelateralpelviclymphnodes |